DRC to launch first phase of Mpox vaccination campaign amid ongoing outbreak
13 oC
13 oC
Güneşli
13 oC
Güneşli
The Democratic Republic of the Congo (DRC), the "epicenter" of Africa's ongoing Mpox outbreak, will begin the first phase of its vaccination campaign on October 2, the government announced.
The campaign, which will run until October 11, follows the receipt of over 265,000 vaccine doses from international partners.
The DRC has reported 21,813 suspected cases of Mpox, with 716 deaths recorded since the beginning of 2024, according to a report released Friday by the Congolese Ministry of Health. The country is responsible for approximately 90 percent of Mpox cases across Africa.
The vaccination campaign comes as the World Health Organization (WHO) approved the MVA-BN vaccine, developed by Bavarian Nordic, for its prequalification list, marking it as the first officially approved vaccine for Mpox. (ILKHA)
LEGAL WARNING: All rights of the published news, photos and videos are reserved by İlke Haber Ajansı Basın Yayın San. Trade A.Ş. Under no circumstances can all or part of the news, photos and videos be used without a written contract or subscription.
A federal judicial panel on Monday ordered that a growing number of lawsuits accusing Novo Nordisk and Eli Lilly of causing vision loss be centralized before a single judge in Pennsylvania, marking a significant new phase in litigation over the widely used weight-loss and diabetes drugs.
Nigeria has confirmed 17 new cases of Lassa fever across four states, according to the latest epidemiological report released by the Nigeria Centre for Disease Control and Prevention (NCDC) for Week 47 (November 17–23, 2025).
New tools, including dual-ingredient insecticide nets and WHO-recommended vaccines, helped prevent an estimated 170 million malaria cases and 1 million deaths in 2024, according to the World Health Organization’s (WHO) annual World Malaria Report.
The World Health Organization (WHO) has issued updated recommendations on the use of glucagon-like peptide-1 (GLP-1) medicines for the treatment of obesity in adults, as the organization warns that obesity is reaching unprecedented levels worldwide.
